These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Identification of 3,4-Dihydro-2 Hartuti ED; Sakura T; Tagod MSO; Yoshida E; Wang X; Mochizuki K; Acharjee R; Matsuo Y; Tokumasu F; Mori M; Waluyo D; Shiomi K; Nozaki T; Hamano S; Shiba T; Kita K; Inaoka DK Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281290 [No Abstract] [Full Text] [Related]
3. A comprehensive review of synthetic strategies and SAR studies for the discovery of PfDHODH inhibitors as antimalarial agents. Part 1: triazolopyrimidine, isoxazolopyrimidine and pyrrole-based (DSM) compounds. Sharma M; Pandey V; Poli G; Tuccinardi T; Lolli ML; Vyas VK Bioorg Chem; 2024 May; 146():107249. PubMed ID: 38493638 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors. Azeredo LFSP; Coutinho JP; Jabor VAP; Feliciano PR; Nonato MC; Kaiser CR; Menezes CMS; Hammes ASO; Caffarena ER; Hoelz LVB; de Souza NB; Pereira GAN; Cerávolo IP; Krettli AU; Boechat N Eur J Med Chem; 2017 Jan; 126():72-83. PubMed ID: 27744189 [TBL] [Abstract][Full Text] [Related]
5. In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth. Ross LS; Gamo FJ; Lafuente-Monasterio MJ; Singh OM; Rowland P; Wiegand RC; Wirth DF J Biol Chem; 2014 Jun; 289(26):17980-95. PubMed ID: 24782313 [TBL] [Abstract][Full Text] [Related]
6. QSAR study on the antimalarial activity of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors. Hou X; Chen X; Zhang M; Yan A SAR QSAR Environ Res; 2016; 27(2):101-24. PubMed ID: 26911561 [TBL] [Abstract][Full Text] [Related]
7. Synthesis, Design, and Structure⁻Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of Xu L; Li W; Diao Y; Sun H; Li H; Zhu L; Zhou H; Zhao Z Molecules; 2018 May; 23(6):. PubMed ID: 29794978 [TBL] [Abstract][Full Text] [Related]
8. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria. Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917 [TBL] [Abstract][Full Text] [Related]
9. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022). Gehlot P; Vyas VK Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439 [TBL] [Abstract][Full Text] [Related]
10. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. Phillips MA; Gujjar R; Malmquist NA; White J; El Mazouni F; Baldwin J; Rathod PK J Med Chem; 2008 Jun; 51(12):3649-53. PubMed ID: 18522386 [TBL] [Abstract][Full Text] [Related]
11. Medicinal chemistry approaches for the discovery of Vyas VK; Shukla T; Sharma M Future Med Chem; 2023 Jul; 15(14):1295-1321. PubMed ID: 37551689 [TBL] [Abstract][Full Text] [Related]
12. Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening. Pavadai E; El Mazouni F; Wittlin S; de Kock C; Phillips MA; Chibale K J Chem Inf Model; 2016 Mar; 56(3):548-62. PubMed ID: 26915022 [TBL] [Abstract][Full Text] [Related]
13. Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity. Vyas VK; Qureshi G; Ghate M; Patel H; Dalai S SAR QSAR Environ Res; 2016 Jun; 27(6):427-40. PubMed ID: 27310104 [TBL] [Abstract][Full Text] [Related]
14. Dihydroorotate dehydrogenase: A drug target for the development of antimalarials. Singh A; Maqbool M; Mobashir M; Hoda N Eur J Med Chem; 2017 Jan; 125():640-651. PubMed ID: 27721149 [TBL] [Abstract][Full Text] [Related]
15. Design and tests of prospective property predictions for novel antimalarial 2-aminopropylaminoquinolones. Clark RD; Morris DN; Chinigo G; Lawless MS; Prudhomme J; Le Roch KG; Lafuente MJ; Ferrer S; Gamo FJ; Gadwood R; Woltosz WS J Comput Aided Mol Des; 2020 Nov; 34(11):1117-1132. PubMed ID: 32833084 [TBL] [Abstract][Full Text] [Related]
16. Deciphering Interactions between Potential Inhibitors and the Lima Costa AH; Bezerra KS; de Lima Neto JX; Oliveira JIN; Galvão DS; Fulco UL J Phys Chem B; 2023 Nov; 127(44):9461-9475. PubMed ID: 37897437 [TBL] [Abstract][Full Text] [Related]
17. Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors. Silveira FF; de Souza JO; Hoelz LVB; Campos VR; Jabor VAP; Aguiar ACC; Nonato MC; Albuquerque MG; Guido RVC; Boechat N; Pinheiro LCS Eur J Med Chem; 2021 Jan; 209():112941. PubMed ID: 33158577 [TBL] [Abstract][Full Text] [Related]
18. Understanding the structural requirements in diverse scaffolds for the inhibition of P. falciparum dihydroorotate dehydrogenase (PfDHODH) using 2D-QSAR, 3D-pharmacophore and structure-based energy- optimized pharmacophore models. Aher RB; Roy K Comb Chem High Throughput Screen; 2015; 18(2):217-26. PubMed ID: 25543684 [TBL] [Abstract][Full Text] [Related]
19. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds. Deng X; Gujjar R; El Mazouni F; Kaminsky W; Malmquist NA; Goldsmith EJ; Rathod PK; Phillips MA J Biol Chem; 2009 Sep; 284(39):26999-7009. PubMed ID: 19640844 [TBL] [Abstract][Full Text] [Related]